3
Announcements
Trials
Browse
Landscape
Phase
Phase 4
1
Status
Withdrawn
1
Sponsor Class
OTHER_GOV
1
Study Type
Interventional
1
Sponsor
Conditions
Opportunistic Infections
1
Inflammation
1
Epstein-Barr Virus Infections
1
Cytomegalovirus Infections
1
Coinfection
1
Acquired Immunodeficiency Syndrome
1
Interventions
Paclitaxel
2
Irinotecan
2
Carboplatin
2
pertuzumab
1
ledipasvir
1
genexol-PM
1
elbasvir-grazoprevir drug combination
1
dolutegravir
1
apatinib
1
Vinorelbine
1
Trastuzumab
1
Tissue Banks
1
Tai Ji
1
Surgical Procedures, Operative
1
Sofosbuvir
1
S 1 (combination)
1
Ritonavir
1
Ribavirin
1
Radiotherapy, Intensity-Modulated
1
Qigong
1
Physical Examination
1
Oxaliplatin
1
Nucleosides
1
Nivolumab
1
Magnesium
1
Levoleucovorin
1
Interleukin-2
1
Immunotherapy
1
Immune Checkpoint Inhibitors
1
Hydralazine
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Withdrawn
×
OTHER_GOV
×
Nucleosides
×
Clear all
NCT04183738
2020-11-10
i2-D²EFT
Kirby Institute
Phase 4
Withdrawn